Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Big antibody deals

Big antibody deals

Partners Year Potential value Description
Genmab (CSE:GEN) GlaxoSmithKline (LSE:GSK; GSK) 2006 $2,059 GSK receives global exclusive rights to co-develop and commercialize GEN's ofatumumab for cancer and autoimmune diseases. The biotech receives a DKK582M ($102M) license fee, a DKK2B ($357M) equity investment and is eligible for up to DKK9B ($1.6B) in milestones plus double-digit royalties.

Read the full 583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE